GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (FRA:3TP0) » Definitions » 14-Day RSI

Acerus Pharmaceuticals (FRA:3TP0) 14-Day RSI : N/A (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Acerus Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-26), Acerus Pharmaceuticals's 14-Day RSI is N/A.

The industry rank for Acerus Pharmaceuticals's 14-Day RSI or its related term are showing as below:

FRA:3TP0's 14-Day RSI is not ranked *
in the Drug Manufacturers industry.
Industry Median: 46.885
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of Acerus Pharmaceuticals's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's 14-Day RSI falls into.



Acerus Pharmaceuticals  (FRA:3TP0) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acerus Pharmaceuticals  (FRA:3TP0) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Acerus Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals (FRA:3TP0) Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus Pharmaceuticals (FRA:3TP0) Headlines

No Headlines